Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma.
Pierre
P
Loulergue
Olivier
O
Mir
Jérôme
J
Allali
Jean-Paul
JP
Viard
D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D000075202:Contraindications; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D000077143:Docetaxel; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005142:Eyelid Neoplasms / Q000188:drug therapy*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D019438:Ritonavir / Q000493:pharmacokinetics*; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D043823:Taxoids / Q000493:pharmacokinetics*
D000970:Antineoplastic Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D017320:HIV Protease Inhibitors; D043823:Taxoids; D000077143:Docetaxel; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D019438:Ritonavir